FrancophonIA/ELRC3.0 huggingface dataset:
English: • to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections;
Slovenian: • za povečanje števila nevtrofilcev in zmanjšanje tveganja za okužbe pri bolnikih z nevtropenijo, ki so imeli v preteklosti hude ponavljajoče se okužbe;
English: Why is Accofil approved?
Slovenian: Za kaj je bilo zdravilo Accofil odobreno?
English: • to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at risk of long-term, severe neutropenia;
Slovenian: • za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo s terapijo, katere cilj je uničenje celic kostnega mozga pred presaditvijo kostnega mozga (npr. pri nekaterih bolnikih z levkemijo), pri katerih obstaja tveganje za dalj časa trajajočo hudo nevtropenijo;
English: How is Accofil used?
Slovenian: Kako se zdravilo Accofil uporablja?
English: How does Accofil work?
Slovenian: Kako zdravilo Accofil deluje?
English: 10 (2 x 5) pre-filled pens (multipack)
Slovenian: 10 (2 x 5) napolnjenih injekcijskih peresnikov (multipakiranje)
English: Content (concentration) Package size
Slovenian: Vsebina (koncentracija)
English: Invented name Strength Pharmaceutical form Route of administration Packaging
Slovenian: Izmišljeno ime Jakost
English: Powder: 1000 IU
Slovenian: Pot uporabe Ovojnina
English: Further information on Carmustine Obvius can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije o zdravilu Karmustin Obvius so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The medicine is used when initial treatment has not worked or the cancer has come back.
Slovenian: Zdravilo se uporablja, kadar začetno zdravljenje ni delovalo ali se je rak ponovil.
English: Carmustine Obvius (carmustine) EMA/273425/2018
Slovenian: Karmustin Obvius (karmustin) EMA/273425/2018
English: • Hodgkin's lymphoma and non-Hodgkin's lymphomas, types of cancer that originate from white blood cells.
Slovenian: • Hodgkinovega limfoma in ne-Hodgkinovih limfomov, tj. vrst raka, ki izvirajo iz belih krvnih celic.
English: • brain tumours, both those that develop directly in the brain and cancers that have spread from elsewhere in the body (metastatic brain tumours);
Slovenian: • možganskih tumorjev, in sicer tistih, ki se razvijejo neposredno v možganih, in rakov, ki so se razširili z drugih delov telesa (metastatskih možganskih tumorjev);
English: It interferes with the normal function and repair of DNA and RNA, the genetic instructions that cells need to function and multiply.
Slovenian: Ovira normalno delovanje in popravljanje DNK in RNK, tj. genetskih navodil, ki jih celice potrebujejo za delovanje in podvajanje.
English: A dose based on the patient's weight and height is given at intervals of at least 6 weeks, and should be adjusted according to the patient's blood cell counts.
Slovenian: Odmerek, ki temelji na bolnikovi telesni masi in višini, se daje v vsaj šesttedenskih presledkih in ga je treba prilagoditi glede na bolnikovo krvno sliko.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Carmustine Obvius has been shown to be comparable to Carmubris.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Karmustin Obvius primerljivo z zdravilom Carmubris.
English: What measures are being taken to ensure the safe and effective use of Carmustine Obvius?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Karmustin Obvius?
English: Carmustine Obvius is a cancer medicine that is used, on its own or with other cancer medicines and treatments, to treat the following types of cancer:
Slovenian: Karmustin Obvius je zdravilo proti raku, ki se uporablja samostojno ali skupaj z drugimi zdravili in zdravljenji za zdravljenje naslednjih vrst raka:
English: Because Carmustine Obvius is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Karmustin Obvius generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: As for every medicine, the company provided studies on the quality of Carmustine Obvius.
Slovenian: Tako kot za vsako zdravilo je družba predložila študije o kakovosti zdravila Karmustin Obvius.
English: An overview of Carmustine Obvius and why it is authorised in the EU
Slovenian: Pregled zdravila Karmustin Obvius in zakaj je odobreno v EU
English: Studies on the benefits and risks of the active substance carmustine in the authorised uses have already been carried out with the reference medicine, Carmubris, and do not need to be repeated for Carmustine Obvius.
Slovenian: Študije o koristih in tveganjih učinkovine karmustina pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Carmubris, zato jih ni treba ponoviti za zdravilo Karmustin Obvius.
English: Other information about Carmustine Obvius
Slovenian: Druge informacije o zdravilu Karmustin Obvius
English: What are the benefits and risks of Carmustine Obvius?
Slovenian: Kakšne so koristi in tveganja zdravila Karmustin Obvius?
English: Carmustine Obvius (carmustine)
Slovenian: Karmustin Obvius (karmustin)
English: What is Carmustine Obvius and what is it used for?
Slovenian: Kaj je zdravilo Karmustin Obvius in za kaj se uporablja?
English: Carmustine Obvius is a ‘generic medicine'.
Slovenian: Zdravilo Karmustin Obvius je „generično zdravilo“.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Carmustine Obvius have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Karmustin Obvius upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: This means that Carmustine Obvius contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Carmubris.
Slovenian: To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Carmubris.
English: By damaging the DNA of cancer cells, carmustine can help kill them and prevent the cancer from growing and spreading.
Slovenian: Karmustin poškoduje DNK rakavih celic, jih tako uniči ter prepreči rast in širjenje raka.
English: Why is Carmustine Obvius authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Karmustin Obvius odobreno v EU?
English: Carmustine, the active substance in this medicine, is a type of cancer medicine known as an alkylating agent.
Slovenian: Karmustin, učinkovina v tem zdravilu, je vrsta zdravila proti raku, znana kot alkilirajoča učinkovina.
English: For more information about using Carmustine Obvius, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Karmustin Obvius glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Side effects reported with Carmustine Obvius are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Karmustin Obvius, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: As for all medicines, data on the use of Carmustine Obvius are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Karmustin Obvius stalno spremljajo.
English: It must be given under the supervision of a doctor experienced in the use of cancer medicines and can only be obtained with a prescription.
Slovenian: Dajati se mora pod nadzorom zdravnika z izkušnjami pri uporabi zdravil proti raku, predpisovanje in izdaja zdravila pa je le na recept.
English: There was no need for ‘bioequivalence' studies to investigate whether Carmustine Obvius is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Slovenian: Izvedba študije bioekvivalence, s katero bi raziskali, ali se zdravilo Karmustin Obvius absorbira podobno kot referenčno zdravilo in tako doseže enake ravni učinkovine v krvi, ni bila potrebna.
English: Because cancer cells tend to grow and multiply more than normal
Slovenian: Ker rakave celice bolj rastejo in razmnožujejo kot normalne celice, so bolj dovzetne za delovanje tega zdravila.
English: This is because Carmustine Obvius is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.
Slovenian: Zdravilo Karmustin Obvius se namreč daje z infundiranjem v veno, tako da učinkovina vstopa neposredno v krvni obtok.
English: Carmustine Obvius is given by infusion (drip) into a vein.
Slovenian: Zdravilo Karmustin Obvius se daje z infundiranjem (kapalno infuzijo) v veno.
English: Therefore, the Agency's view was that, as for Carmubris, the benefit of Carmustine Obvius outweighs the identified risk and it can be authorised for use in the EU.
Slovenian: Zato je menila, da koristi zdravila Karmustin Obvius enako kot pri zdravilu Carmubris odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
English: How has Carmustine Obvius been studied?
Slovenian: Kako je bilo zdravilo Karmustin Obvius raziskano?
English: How is Carmustine Obvius used?
Slovenian: Kako se zdravilo Karmustin Obvius uporablja?
English: How does Carmustine Obvius work?
Slovenian: Kako zdravilo Karmustin Obvius deluje?
English: Date of first authorisation: 26 June 2006 Date of latest renewal: 26 June 2011
Slovenian: Datum prve odobritve: 26. junij 2006 Datum zadnjega podaljšanja: 26. junij 2011
English: That expiry date refers to the last day of that month.
Slovenian: Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
English: After each use, rinse the spoon with water and allow it to air dry.
Slovenian: Po vsaki uporabi žličko splaknite z vodo in jo posušite na zraku.
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal
Slovenian: Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
English: Iron oxide red
Slovenian: rdeči železov oksid
English: PC: SN: <NN:>
Slovenian: SN: <NN:>
English: ULN=upper limit of normal, LLN=lower limit of normal.
Slovenian: ULN=zgornja meja normalne vrednosti, LLN=spodnja meja normalne vrednosti.
English: 10.7% e 27% e 41.3% e
Slovenian: 10,7% e 27% e 41,3% e 43,6% e a
English: Baraclude with food and drink
Slovenian: Zdravilo Baraclude skupaj s hrano in pijačo
English: In most cases you may take Baraclude with or without food.
Slovenian: V večini primerov lahko zdravilo Baraclude jemljete skupaj s hrano ali brez nje.
English: Baraclude reduces the amount of virus in your body, and improves the condition of the liver.
Slovenian: Zdravilo Baraclude zmanjša količino virusa v telesu in izboljša stanje jeter.
English: Keep the bottle in the outer carton in order to protect from light.
Slovenian: Plastenko shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
English: Each carton contains either:
Slovenian: Vsaka škatla vsebuje:
English: The measuring spoon is manufactured by: Comar Plastics Division, One Comar Place, Buena, NJ 08310, USA.
Slovenian: Izdelovalec merilne žličke: Comar Plastics Division, One Comar Place, Buena, NJ 08310, ZDA.
English: This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodiumfree'.
Slovenian: To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na ml, kar v bistvu pomeni ‘brez natrija'.
English: Stable or improved CTP scoreb,d MELD score
Slovenian: Stabilna ali izboljšana ocena po lestvici CTPb,d
English: Swallow the medicine directly from the measuring spoon.
Slovenian: Zdravilo pogoltnite neposredno iz merilne žličke.
English: By 48 weeks of post-treatment follow-up, a substantial number of HBeAg negative patients lost response.
Slovenian: Pri 48-tedenskem spremljanju po zdravljenju se je pri znatnem števili HBeAg negativnih bolnikov odziv izgubil.
English: Authorised Representative in the EEA for Comar Plastics: MDSS GmbH, Schiffgraben 41, 30175 Hannover, Germany
Slovenian: Pooblaščeni zastopnik za Comar Plastics v Evropskem gospodarskem prostoru: MDSS GmbH, Schiffgraben 41, 30175 Hannover, Nemčija.
English: Some patients must take Baraclude on an empty stomach (see Baraclude with food and drink in Section 2).
Slovenian: Nekateri bolniki morajo jemati zdravilo Baraclude na prazen želodec (glejte Zdravilo Baraclude skupaj s hrano in pijačo v poglavju 2).
English: If you forget to take Baraclude
Slovenian: Če ste pozabili vzeti zdravilo Baraclude
English: Normalization of:f
Slovenian: Normalizacija vrednosti:e
English: Frequency is defined as very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000).
Slovenian: Pogostnost je definirana kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000).
English: Luxembourg/Luxemburg
Slovenian: Luxembourg/Luxemburg N.V.
English: The on-study cumulative rate of hepatocellular carcinoma (HCC) was 12% (12/102).
Slovenian: Kumulativni delež pojavnosti hepatocelularnega karcinoma (HCC) med študijo je znašal 12% (12/102).
English: Hold the spoon in a vertical (upright) position and fill it gradually to the mark corresponding to the prescribed dose.
Slovenian: Žličko držite navpično (pokonci) in jo počasi napolnite do oznake, ki označuje predpisani odmerek.
English: Take Baraclude as long as your doctor has told you.
Slovenian: Zdravilo Baraclude jemljite tako dolgo, kot vam je predpisal zdravnik.
English: Patients may be dosed with or without food.
Slovenian: Bolniki lahko odmerek jemljejo s hrano ali brez nje.
English: A 4 hour period of haemodialysis removed ≈ 13% of the dose, and 0.3% was removed by CAPD.
Slovenian: Pri 4urni hemodializi se je odstranilo ≈ 13% odmerka, pri CAPD pa 0,3%.
English: The correct dose of Baraclude oral solution for children and adolescents is calculated by body weight and is taken once daily orally (by mouth) as shown below:
Slovenian: Pravilen odmerek Baraclude peroralne raztopine za otroke in mladostnike se izračuna na osnovi telesne mase, bolnik pa ga jemlje peroralno (skozi usta) enkrat na dan kot je prikazano v nadaljevanju:
English: Do not dilute or mix this solution with water or anything else.
Slovenian: Raztopine ne smete redčiti ali jo mešati z vodo ali s čim drugim.
English: Children and adolescents (from 2 to less than 18 years of age) can take Baraclude with or without food.
Slovenian: Otroci in mladostniki (stari od 2 leti do manj kot 18 let) lahko zdravilo Baraclude jemljejo skupaj s hrano ali brez nje.
English: Baraclude belongs to a class of medicines that can cause lactic acidosis (excess of lactic acid in your blood) and enlargement of the liver.
Slovenian: zdravilo Baraclude spada v skupino zdravil, ki lahko povzročijo laktacidozo (čezmerno kopičenje mlečne kisline v krvi) in povečanje jeter.
English: This medicinal product must not be mixed with water, other solvents or other medicinal products.
Slovenian: Zdravila ne smemo mešati z vodo, drugimi topili ali drugimi zdravili.
English: Baraclude will not control your HIV infection.
Slovenian: Zdravilo Baraclude ne more nadzirati okužbe z virusom HIV.
English: It is important that women of childbearing age receiving treatment with Baraclude use an effective method of contraception to avoid becoming pregnant.
Slovenian: Pomembno je, da ženske v rodni dobi med zdravljenjem z zdravilom Baraclude za preprečitev nosečnosti uporabljajo učinkovito metodo kontracepcije.
English: If you miss a dose of Baraclude, take it as soon as possible, and then take your next scheduled dose at its regular time.
Slovenian: Pozabljeni odmerek zdravila Baraclude vzemite takoj, ko je to mogoče, naslednji odmerek pa nato vzemite ob običajnem času.
English: Holding the spoon with the volume marks facing you, check that it has been filled to the proper mark.
Slovenian: Žličko držite tako, da so volumske oznake obrnjene k vam in preverite, da je napolnjena do ustrezne oznake.
English: discuss with your doctor whether your liver functions properly and, if not, what the possible effects on your Baraclude treatment may be.
Slovenian: vprašajte svojega zdravnika ali vaša jetra delujejo normalno, in če ne, kako lahko nenormalno delovanje jeter vpliva na zdravljenje z zdravilom Baraclude.
English: do not stop taking Baraclude without your doctor's advice since your hepatitis may worsen after stopping treatment.
Slovenian: zdravila Baraclude ne smete nehati jemati brez nasveta zdravnika, saj se hepatitis po prekinitvi zdravljenja lahko poslabša.
English: Healthcare professionals are asked to report any suspected adverse reactions the national reporting system listed in Appendix V.
Slovenian: Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
English: If you were switched over to Baraclude because the treatment with lamivudine was not successful, you should take Baraclude on an empty stomach once daily.
Slovenian: V primeru zamenjave zdravljenja, če vam je zdravnik zdravilo Baraclude predpisal zato, ker je bilo predhodno zdravljenje z zdravilom z učinkovino lamivudin neuspešno, morate zdravilo Baraclude jemati enkrat na dan na prazen želodec.
English: Name and address of the manufacturer responsible for batch release Bristol-Myers Squibb S.r.l., Contrada Fontana del Ceraso, 03012 Anagni (FR), Italy
Slovenian: A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca, odgovornega za sproščanje serij Bristol-Myers Squibb S.r.l., Contrada Fontana del Ceraso, 03012 Anagni (FR), Italija
English: Other medicines and Baraclude
Slovenian: Druga zdravila in zdravilo Baraclude
English: Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Slovenian: Bolniki z redko dedno težavo intolerance za fruktozo tega zdravila ne smejo jemati.
English: Lactose: this medicinal product contains 120.5 mg of lactose in each 0.5 mg daily dose or 241 mg of lactose in each 1 mg daily dose.
Slovenian: Laktoza: Zdravilo vsebuje 120,5 mg laktoze v vsakem 0,5 mg dnevnem odmerku ali 241 mg laktoze v vsakem 1 mg dnevnem odmerku.
English: HBV DNA < 50 IU/mL and HBeAg seroconversiona HBV DNA < 50 IU/mLa HBeAg seroconversiona ALT normalizationa
Slovenian: HBV DNA < 50 i.e./ml in serokonverzija HBeAga HBV DNA < 50 i.e./mla Serokonverzija HBeAga Normalizacija ALTa
English: Baraclude should not be used during pregnancy unless clearly necessary.
Slovenian: Zdravila Baraclude ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
English: Substitutions observed in clinical isolates (rtT184A, C, F, G, I, L, M or S; rtS202 C, G or I; and/or rtM250I, L or V) further decreased entecavir susceptibility 16- to 741-fold relative to wild-type virus.
Slovenian: Substitucije, ki so jih opazili pri kliničnih izolatih (rtT184A, C, F, G, I, L, M ali S; rtS202 C, G ali I; in/ali rtM250I, L ali V), v primerjavi z divjim tipom virusa še dodatno zmanjšajo občutljivost za entekavir za 16- do 741krat.
English: Severe Managed with CAPD
Slovenian: Zdravljenje s CAPD
English: You should not take Baraclude to treat your hepatitis B infection unless you are taking medicines for HIV at the same time, as the effectiveness of future HIV treatment may be reduced.
Slovenian: Zdravila Baraclude za zdravljenje okužbe z virusom hepatitisa B ne smete jemati, če sočasno ne jemljete tudi zdravil za zdravljenje okužbe z virusom HIV, saj se v nasprotnem primeru lahko učinkovitost zdravil za zdravljenje okužbe z virusom HIV v prihodnosti zmanjša.
English: Excipients with known effect 380 mg maltitol/ml 1.5 mg methylhydroxybenzoate/ml 0.18 mg propylhydroxybenzoate/ml 0.3 mg sodium/ml
Slovenian: Pomožne snovi z znanim učinkom 380 mg maltitola/ml 1,5 mg metilparahidroksibenzoata/ml 0,18 mg propilparahidroksibenzoata/ml 0,3 mg natrija/ml
English: HBV DNA < 50 IU/mLa
Slovenian: HBV DNA < 50 i.e./mla
English: This medicinal product contains maltitol.
Slovenian: Zdravilo vsebuje maltitol.
English: Maltitol: Baraclude oral solution contains maltitol.
Slovenian: Maltitol: Baraclude peroralna raztopina vsebuje maltitol.
English: Baraclude is eliminated from your body through the kidneys and your dose or dosing schedule may need to be adjusted.
Slovenian: To je pomembno, ker se zdravilo Baraclude iz telesa izloča skozi ledvice in vam bo zdravnik morda moral odmerek ali odmerno shemo prilagoditi.
English: For children and adolescents (from 2 to less than 18 years of age), Baraclude oral solution or Baraclude 0.5 mg tablets are available
Slovenian: Za otroke in mladostnike (stare od 2 leti do manj kot 18 let), je zdravilo Baraclude na voljo v obliki peroralne raztopine ali 0,5 mg tablet
English: The recommended once-daily dose in paediatric patients weighing at least 10 kg, is presented in the table below.
Slovenian: Priporočeno odmerjanje enkrat na dan pri pediatričnih bolnikih s telesno maso vsaj 10 kg je prikazano v spodnji preglednici.
English: The safety and efficacy of entecavir were also evaluated in an active-controlled clinical trial of 191 HBVinfected patients with decompensated liver disease and in a clinical trial of 68 patients co-infected with HBV and HIV.
Slovenian: Varnost in učinkovitost entekavirja so vrednotili tudi v aktivno nadzorovanem kliničnem preskušanju, izvedenem pri 191 bolnikih, ki so bili okuženi z virusom HBV in so imeli dekompenzirano bolezen jeter, ter v kliničnem preskušanju pri 68 bolnikih, ki so bili sočasno okuženi z virusom HBV in virusom HIV.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine.
Slovenian: Bolniki z redkimi dednimi težavami, kot so intoleranca za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze/galaktoze tega zdravila ne smejo jemati.
English: Also contains lactose monohydrate.
Slovenian: SEZNAM POMOŽNIH SNOVI Vsebuje tudi laktozo monohidrat.
English: As an alternative, in case the oral solution is not available, the dose can be adjusted by increasing the dosage interval, also shown in the table.
Slovenian: Če peroralne raztopine ni na voljo, se odmerek alternativno lahko prilagodi tudi s podaljšanjem odmernega intervala, kar je tudi prikazano v preglednici.
English: Sodium: Each ml of this medicinal product contains 0.015 mmol (or 0.3 mg) sodium.
Slovenian: Natrij: En ml tega zdravila vsebuje 0,015 mmol (ali 0,3 mg) natrija.
English: What Baraclude is and what it is used for What you need to know before you take Baraclude How to take Baraclude
Slovenian: Kaj je zdravilo Baraclude in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Baraclude Kako jemati zdravilo Baraclude Možni neželeni učinki
English: decompensated liver disease (see section 4.4).
Slovenian: z dekompenzirano boleznijo jeter (glejte poglavje 4.4).
English: Mechanism of action: entecavir, a guanosine nucleoside analogue with activity against HBV polymerase, is efficiently phosphorylated to the active triphosphate (TP) form, which has an intracellular half-life of 15 hours.
Slovenian: Mehanizem delovanja: Entekavir je nukleozidni analog gvanozina, ki deluje proti polimerazi HBV in se učinkovito fosforilizira v aktivno trifosfatno (TP) obliko, katere znotrajcelični razpolovni čas je 15 ur.